Pharma BD Deal Intelligence
Not actually an "Alkermes acquires Cephalon" deal — it was Alkermes reclaiming full Vivitrol rights from a failed 2005 co-promotion, and that reclaimed asset became a genuine blockbuster ($467.9M in 2025 sales).
Full analysis, sources & comparables →The Termination Agreement is intended to reduce the Company's cost structure and enhance competitiveness; Cephalon will incur estimated pretax charges of…
Cephalon CEO Frank Baldino stated 'we have a lot of opportunities on our plate and cannot give Vivitrol the focus it deserves' — framing the JV unwind as a…
Carries Alkermes' positive framing of the rights return: 'Overall, we are very pleased to have worked with Cephalon. The collaboration funded key market…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Termination of Vivitrol JV; Alkermes regained full US commercialization rights; $11M from Cephalon (loss share) + $16M Alkermes manufacturing equipment buyback; ~$120M deferred revenue recognized
Not actually an "Alkermes acquires Cephalon" deal — it was Alkermes reclaiming full Vivitrol rights from a failed 2005 co-promotion, and that reclaimed asset became a genuine blockbuster ($467.9M in 2025 sales).
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Alkermes plc / Cephalon, Inc. (Vivitrol rights) (this deal) | 2008 | $27M | 83 |
| Alkermes plc / Rodin Therapeutics, Inc. | 2019 | $950M | — |
| ViroPharma Incorporated / Lev Pharmaceuticals, Inc. | 2008 | $443M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Sanofi-Aventis / Symbion Consumer (Primary Health Care) | 2008 | $544M | 71 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
← Browse all deals · How we score deals
More: 2008 deals